Migraine treatment strategies: The global Migraine and Zolmitriptan Evaluation (MAZE) survey - Phase IV

Current Medical Research and Opinion

Volumn 20, Issue 11, 2004, Pages 1777-1783

  MacGregor, E Anne ^a   Brandes, Jan ^b   Gendolla, Astrid ^c   Giammarco, Rose ^d  

^a City of London Migraine Clinic   (United Kingdom)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF DUISBURG ESSEN   (Germany)

^d MCMASTER UNIVERSITY   (Canada)

Author keywords

MAZE; Migraine treatment; Over the counter drugs; Survey; Triptans; Zolmitriptan

Indexed keywords

ACETYLSALICYLIC ACID; ANALGESIC AGENT; CODEINE; HERBACEOUS AGENT; HOMEOPATHIC AGENT; IBUPROFEN; NON PRESCRIPTION DRUG; PARACETAMOL; ZOLMITRIPTAN;

ADULT; CONFERENCE PAPER; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; HEALTH CARE ACCESS; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; MIGRAINE; PATIENT SATISFACTION; PHYSICIAN; PRESCRIPTION; UNITED KINGDOM;

ADULT; DRUGS, NON-PRESCRIPTION; FEMALE; GREAT BRITAIN; HUMANS; MALE; MIDDLE AGED; MIGRAINE DISORDERS; OXAZOLIDINONES; PATIENT SATISFACTION; PATIENTS; PRESCRIPTIONS, DRUG; QUESTIONNAIRES; SEROTONIN AGONISTS; TRYPTAMINES;

EID: 10044225588     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079904X10142     Document Type: Conference Paper

References (24)

1. MacGregor EA, Brandes J, Eikermann A. Migraine prevalence and treatment patterns: the global Migraine and Zolmitriptan Evaluation study. Headache 2003;43:19-26
2. Terwindt GM, Ferrari MD, Tijhuis M, Groenen SM, Picavet HS, Launer LJ. The impact of migraine on quality of life in the general population. The GEM study. Neurology 2000;55:624-9
3. Solomon GD, Santanello N. Impact of migraine and migraine therapy on productivity and quality of life. Neurology 2000;55(Suppl. 2):529-35
4. MacGregor EA, Brandes J, Eikermann A, Giammarco R. Impact of migraine on patients and their families: the Migraine and Zolmitriptan Evaluation (MAZE) survey - phase III. Curr Med Res Opin 2004;20:1143-50
5. Lucas C, Auray JP, Gaudin AF, et al. Use and misuse of triptans in France: data from the GRIM2000 population survey. Cephalalgia 2004;24:197-205
6. Dowson A, Jagger S. The UK migraine patient survey: quality of life and treatment. Curr Med Res Opin 1999;15:241-53
7. Lipton RB, Stewart WF, Simon D. Medical consultation for migraine: results from the American Migraine Study. Headache 1998;38:87-96
8. Stang PE, Von Korff M. The diagnosis of headache in primary care: factors in the agreement of clinical and standardized diagnoses. Headache 1994;34:138-42
9. Richard A, Massiou H, Herrmann MA. Frequency and profile of migraine patients seen by general practitioners. Semin Hop Paris 1999;75:440-6
10. Ferrari MD. The economic burden of migraine to society. Pharmacoeconomics 1998;13:667-76
11. Lipton RB, Stewart WF. Acute migraine therapy: do doctors understand what patients with migraine want from therapy. Headache 1999;39(Suppl. 2):S20-6
12. Dowson AJ, Lipscombe S, Sender J, Rees T, Watson D. MIPCA Migraine Guidelines Development Group. Migraine In Primary Care Advisors. New guidelines for the management of migraine in primary care. Curr Med Res Opin 2002;18:414-39
13. Matchar DB, Young WB, Rosenberg JH, et al. Evidence-based guidelines for migraine headache in the primary care setting: pharmacological management of acute attacks. Available at: http://www.aan.com/professionals/practice/pdfs/ g10087.pdf [Accessed 6 April 2004]
14. Ceballos Hernansanz MA, Sanchez Roy R, Cano Orgaz A, Lopez-Gil A. START 10 Study Group. Migraine treatment patterns and patient satisfaction with prior therapy: a substudy of a multicenter trial of rizatriptan effectiveness. Clin Ther 2003;25:2053-69
15. Edmeads J, Findlay H, Tugwell P, Pryse-Phillips W, Nelson RF, Murray TJ. Impact of migraine and tension-type headache on life-style, consulting behaviour, and medication use: a Canadian population survey. Can J Neurol Sci 1993;20:131-7
16. Lipton RB, Diamond S, Reed M, Diamond ML, Stewart WF. Migraine diagnosis and treatment: results from the American Migraine Study II. Headache 2001;41:638-45
17. Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 2001;41:646-57
18. Stewart WF, Lipton RB, Kolodner K, Liberman J, Sawyer J. Reliability of the Migraine Disability Assessment score in a population-based sample of headache sufferers. Cephalalgia 1999;19:107-14
19. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988;8(Suppl. 7):1-96
20. Silberstein SD, for the US Headache Consortium. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000;55:754-63
21. Lipton RB, Scher AI, Kolodner K, Liberman J, Steiner TJ, Stewart WF. Migraine in the United States. Epidemiology and patterns of health care use. Neurology 2002;58:885-94
22. Celentano DD, Stewart WF, Lipton RB, Reed ML. Medication use and disability among migraineurs: a national probability sample survey. Headache 1992;32:223-8
23. Dahlöf C. Integrating triptans into clinical practice. Curr Opin Neurol 2002;15:317-22
24. Robbins L. Triptans versus analgesics. Headache 2002;42:903-7